172 episodes

Keeping you up to date with the latest in rheumatology and cytokine signalling

Cytokine Signalling Forum Cytokine Signalling Forum

    • Education
    • 5.0 • 6 Ratings

Keeping you up to date with the latest in rheumatology and cytokine signalling

    Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness

    Rheumatology Author Professor Paul Bird: Tofacitinib Effectiveness

    Paul Bird, Conjoint Professor at the University of South Wales. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Paul Bird assess the real‑world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia.

    • 19 min
    Discussing Rheumatology: Poor Prognostic Factors, Monotherapy, and Combination Therapy

    Discussing Rheumatology: Poor Prognostic Factors, Monotherapy, and Combination Therapy

    Prof Iain McInnes discusses poor prognostics factors from the FINCH 3 study, and the effectiveness and persistence of monotherapy and combination therapy from the Australian OPAL study.
    Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

    • 8 min
    Rheumatology Author Professor Kurt de Vlam: Pain Improvements

    Rheumatology Author Professor Kurt de Vlam: Pain Improvements

    Kurt de Vlam, Professor of Rheumatology at UZ Leuven, Belgium. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor de Vlam assess the impact of baseline pain severity on pain response and the time to improvement in patients with PsA receiving tofacitinib.

    • 28 min
    Rheumatology Author Professor Strand: Upadacitinib and PROs

    Rheumatology Author Professor Strand: Upadacitinib and PROs

    Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology/Rheumatology, Biopharmaceutical Consultant at Stanford University School of Medicine.
    Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Strand discusses improvements in PROs in patients with RA treated with upadacitinib monotherapy.

    • 25 min
    Discussing Rheumatology: Patient Reported Outcomes

    Discussing Rheumatology: Patient Reported Outcomes

    Prof Iain McInnes discusses an essential part of the assessment of patients with rheumatic diseases; patient reported outcomes, or PROs. Improving PROs is crucial to effect tangible change in diseases and patient outcomes - to the extent that PROs are now included as an important component of many clinical trials.
    Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

    • 12 min
    Discussing Rheumatology: SELECT-PsA 2 and DMARDs in COVID-19

    Discussing Rheumatology: SELECT-PsA 2 and DMARDs in COVID-19

    Prof Iain McInnes discusses long-term data from the SELECT-PsA 2 study, and the impact of DMARDs on COVID-19 outcomes.
    Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

    • 9 min

Customer Reviews

5.0 out of 5
6 Ratings

6 Ratings

Top Podcasts In Education

You Might Also Like